Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

More articles from Article

  • The Biological Sequelae of Stromal Cell-derived Factor-1α in Multiple Myeloma 1 This work was supported by Multiple Myeloma Research Foundation Senior Awards (to T. H. and D. C.), Leukemia and Lymphoma Society Scholar Award (to N. M.), NIH Grant PO-1 78378, and the Doris Duke Distinguished Clinical Research Scientist Award (to K. A.).1
    Teru Hideshima, Dharminder Chauhan, Toshiaki Hayashi, Klaus Podar, Masaharu Akiyama, Deepak Gupta, Paul Richardson, Nikhil Munshi, Kenneth C. Anderson
    Molecular Cancer Therapeutics May 2002, 1 (7) 539-544;
  • Interaction of the Novel Anthracycline Antitumor Agent N-Benzyladriamycin-14-valerate with the C1-Regulatory Domain of Protein Kinase C: Structural Requirements, Isoform Specificity, and Correlation with Drug Cytotoxicity 1 Supported by CA 44890 (to T. W. S.), CA 74197 (to M. G. K.), ACS RPG-97-092-01-CNE (to M. G. K.), NIH Medical Student Research Fellowship T35 DK07405-11 (to J. B. R.), and the Computational Research on Materials Institute at the University of Memphis.1
    J. Brent Roaten, Marcelo G. Kazanietz, Maria Jose Caloca, Paul J. Bertics, Leonard Lothstein, Abby L. Parrill, Mervyn Israel, Trevor W. Sweatman
    Molecular Cancer Therapeutics May 2002, 1 (7) 483-492;
  • Homocysteine and Methylmalonic Acid: Markers to Predict and Avoid Toxicity from Pemetrexed Therapy 1 Supported by Eli Lilly and Company.1
    Clet Niyikiza, Sharyn D. Baker, David E. Seitz, Jackie M. Walling, Katrina Nelson, James J. Rusthoven, Sally P. Stabler, Paolo Paoletti, A. Hilary Calvert, Robert H. Allen
    Molecular Cancer Therapeutics May 2002, 1 (7) 545-552;
  • Retinoic Acid-induced Growth Arrest and Differentiation: Retinoic Acid Up-Regulates CD32 (FcγRII) Expression, the Ectopic Expression of Which Retards the Cell Cycle 1 Supported in part by grants from the NIH (USPHS) and United States Department of Agriculture. J. W. and T. J. L. are recipients of National Institute of Environmental Health Sciences Training Fellowship ESO7052.1
    Jenifer Wightman, Mark S. Roberson, Thomas J. Lamkin, Susi Varvayanis, Andrew Yen
    Molecular Cancer Therapeutics May 2002, 1 (7) 493-506;
  • Systemic Tumor-targeted Gene Delivery by Anti-Transferrin Receptor scFv-Immunoliposomes 1 This work was supported in part by National Cancer Institute Grant R01 CA45158 (to E. C.), National Cancer Institute Small Business Technology Transfer Phase I Grant R41 CA80449 (to E. C.), and a grant from SynerGene Therapeutics, Inc.1
    Liang Xu, Cheng-Cheng Huang, Weiqun Huang, Wen-Hua Tang, Antonina Rait, Yu Zhi Yin, Idalia Cruz, Lai-Man Xiang, Kathleen F. Pirollo, Esther H. Chang
    Molecular Cancer Therapeutics Mar 2002, 1 (5) 337-346;
  • Antiangiogenic Effect by SU5416 Is Partly Attributable to Inhibition of Flt-1 Receptor Signaling 1 Supported by grant-in-aid for Cancer Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan.1
    Takashi Itokawa, Hiroki Nokihara, Yasuhiko Nishioka, Saburo Sone, Yukihide Iwamoto, Yuji Yamada, Julie Cherrington, Gerald McMahon, Masabumi Shibuya, Michihiko Kuwano, Mayumi Ono
    Molecular Cancer Therapeutics Mar 2002, 1 (5) 295-302;
  • Mitogen-activated Protein/Extracellular Signal-regulated Kinase Kinase (MEK) Inhibitors Restore Anoikis Sensitivity in Human Breast Cancer Cell Lines with a Constitutively Activated Extracellular- regulated Kinase (ERK) Pathway 1 This work was supported by a Grant-in-Aid for Cancer Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.1
    Hidesuke Fukazawa, Kohji Noguchi, Yuko Murakami, Yoshimasa Uehara
    Molecular Cancer Therapeutics Mar 2002, 1 (5) 303-309;
  • Establishing Connections between Microarray Expression Data and Chemotherapeutic Cancer Pharmacology 1 Supported in whole or in part with federal funds from the National Cancer Institute, NIH, under Contract No. NO1-CO-56000.1
    Anders Wallqvist, Alfred A. Rabow, Robert H. Shoemaker, Edward A. Sausville, David G. Covell
    Molecular Cancer Therapeutics Mar 2002, 1 (5) 311-320;
  • A Model System for the Design of Armed Replicating Adenoviruses Using p53 as a Candidate Transgene 1 Supported by the Israel-University of Alabama at Birmingham Medical Exchange Fund (Y. S. H.) and by grants from the United States Department of Defense (DAMD17-00-1-0002 and DAMD17-98-1-8571), the National Cancer Institute (R01 CA83821, IT32 CA75930, and P50 CA83591), the Lustgarten Foundation (LF043), and the CaPCURE Foundation (to D. T. C.).1
    Yosef S. Haviv, Koichi Takayama, Joel N. Glasgow, Jerry L. Blackwell, Minghui Wang, Xiaosheng Lei, David T. Curiel
    Molecular Cancer Therapeutics Mar 2002, 1 (5) 321-328;
  • PAGE4 Is a Cytoplasmic Protein That Is Expressed in Normal Prostate and in Prostate Cancers
    Carlo Iavarone, Curt Wolfgang, Vasantha Kumar, Paul Duray, Mark Willingham, Ira Pastan, Tapan K. Bera
    Molecular Cancer Therapeutics Mar 2002, 1 (5) 329-335;

Pages

  • Previous
  • Next
  • 1
  • …
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement